Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

p>

Financials results included below:

SemBioSys Genetics Inc.

Consolidated Balance Sheets

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars)

June 30, December 31,

2008 2007

$ $

------------ ------------

Assets

Current assets

Cash and cash equivalents 14,101,923 20,444,013

Accounts receivable 228,300 613,912

Prepaid expenses and deposits 317,810 538,718

Inventory 743,568 426,641

------------ ------------

15,391,601 22,023,284

Property and equipment 8,969,956 9,272,415

------------ ------------

24,361,557 31,295,699

------------ ------------

------------ ------------

Liabilities

Current liabilities

Accounts payable and accrued liabilities 1,673,651 1,875,397

Short-term portion of long-term debt 563,201 629,479

------------ ------------

2,236,852 2,504,876

Deferred cost recoveries 207,527 286,596

Long-term debt 1,216,830 759,568 '/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email: